Skip to content

About
Science
- Overview
- Publications
Pipeline
Investors
Careers
Contact

About
Science
- Overview
- Publications
Pipeline
Investors
Careers
Contact

Press Releases

Choose Year
Search Press Releases

Found 86 Results

October 6, 2022

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

September 26, 2022

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

August 11, 2022

Surrozen Reports Second Quarter 2022 Financial Results

June 13, 2022

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

May 24, 2022

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

May 18, 2022

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

May 16, 2022

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic,Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease (IBD)

May 11, 2022

Surrozen Reports First Quarter 2022 Financial Results

May 5, 2022

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

May 2, 2022

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

«...3 456 7...»

IR Contact

Email: investorinfo@surrozen.com

Email Alerts Sign-Up

Email

Unsubscribe

Loading...

Company

About
Management
Board of Directors
Scientific Advisors
Contact
Careers

Science

Science
Pipeline
Publications

Investors

Overview
News
Events
SEC Filings
Corporate Governance
Stock Information
FAQs

Copyright © 2026 Surrozen. All Rights Reserved

FCOI Policy
Accessibility

Scroll to Top